Vaccines against COVID-19 could be available as early as the end of this year, and Russia has already granted full regulatory approval to its vaccine candidate. inDemic.org tracks the clinical development, regulatory milestones, and manufacturing capacity associated with each of the most promising vaccines to show not only when vaccines could be approved but also when they could be rolled out for at-risk populations (e.g. healthcare workers) and the general public. Comments or questions regarding the Vaccines Timeline can be sent anytime to firstname.lastname@example.org.
Here, we describe the timeline for COVID-19 vaccines, specifically US and European vaccine candidates under investigation in phase 3 clinical trials. Currently, Pfizer and Moderna’s vaccine trials are progressing according to schedule, while AstraZeneca and JNJ’s vaccine trials have been delayed due to safety concerns. Like the CanSino and Gamaleya vaccines in China and Russia, respectively, we expect that vaccine candidates in the USA and Europe will be gradually rolled out, first to at-risk populations (e.g. healthcare workers), and later to the general public after additional safety and efficacy data has accumulated.